Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Currently submitted to: JMIR Research Protocols

Date Submitted: Feb 5, 2026
Open Peer Review Period: Feb 6, 2026 - Apr 3, 2026
(currently open for review)

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Frequency, Clinical Outcomes, Anatomical Distribution, and Management Implications of Thromboembolic Complications Associated with Cardiac Myxomas: Protocol for a Systematic Review

  • Arun Dahil; 
  • Callum Hill; 
  • David Hardisty; 
  • Piotr Wasilewski; 
  • Cameron Pinn; 
  • Matthew Turner; 
  • Michaela Scheuermann-Freestone

ABSTRACT

Background:

Cardiac myxomas (CMs) are the most common benign primary cardiac tumours, most frequently originating from the left atrium, and less commonly from the right atrium. Despite being histologically benign, CMs can cause serious thromboembolic complications including stroke, acute coronary syndrome, limb ischemia, and visceral infarction. While previous studies have explored risk factors for thromboembolism, literature comprehensively synthesising the anatomical distribution, clinical patterns, and management of CMs remains limited.

Objective:

We intend to summarise the published evidence on the frequency, anatomical distribution, clinical presentations, and management implications of thromboembolic events associated with CMs.

Methods:

A systematic review will be conducted in accordance with PRISMA-P guidelines and registered on PROSPERO. Medline, Embase, and PubMed will be searched for studies reporting thromboembolic complications in patients with histologically or radiologically confirmed CMs. Eligible study designs include case reports, case series, cohort studies, and registries. Two reviewers will independently screen studies and extract data on patient demographics, tumour characteristics, embolic events (type, site, clinical presentation), diagnostics, management, and outcomes. Discrepancies will be resolved through discussion or third-party adjudication. Risk of bias will be assessed using Joanna Briggs Institute tools.

Results:

The review will summarise reported frequencies and anatomical distribution of embolic events, clinical presentations, associations with tumour characteristics, and management strategies. Case reports will be tabulated individually, while cohort and series data will be aggregated descriptively with quantitative summaries presented where feasible.

Conclusions:

This review aims to provide a comprehensive synthesis of thromboembolic complications associated with CMs, highlighting patterns, management strategies, and gaps in the current literature. Findings aim to improve clinical recognition, inform clinical management, and guide future research. Clinical Trial: This study is a systematic review and not a clinical trial. The review protocol was prospectively registered with PROSPERO (CRD420261299634).


 Citation

Please cite as:

Dahil A, Hill C, Hardisty D, Wasilewski P, Pinn C, Turner M, Scheuermann-Freestone M

Frequency, Clinical Outcomes, Anatomical Distribution, and Management Implications of Thromboembolic Complications Associated with Cardiac Myxomas: Protocol for a Systematic Review

JMIR Preprints. 05/02/2026:92926

DOI: 10.2196/preprints.92926

URL: https://preprints.jmir.org/preprint/92926

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.